Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma)...

phase 3 randomized, open-label, clinical trial of Pexa-Vec plus sorafenib versus sorafenib is being conducted on patients with advanced hepatocellular carcinoma...

people with hepatocellular carcinoma who have been previously treated with sorafenib. The approval was based on CELESTIAL (NCT01908426), a randomized (2:1)...

therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear cell carcinoma"...

partner at Institutional Venture Partners (an original Onyx backer). Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name...

and various receptor tyrosine kinases. It is a deuterated derivative of sorafenib with improved pharmacokinetic properties. Keam, Susan J.; Duggan, Sean...

molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors...

diastolic was reported in the first 24 hours after the first treatment with sorafenib, a VEGF pathway inhibitor.[non-primary source needed] Because these drugs...

Peginterferon alfa-2b is being studied to treat plexiform neurofibromas. Sorafenib is being studied for treatment of unresectable plexiform neurofibroma...

showed significantly extended progression-free survival when compared to sorafenib. In December 2011, the Oncologic Drugs Advisory Committee (ODAC) voted...